Literature DB >> 15981921

Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates.

Jianjun Cheng1, Kay T Khin, Mark E Davis.   

Abstract

Antitumor activity of linear, beta-cyclodextrin polymer (CDP)-camptothecin (CPT) conjugates (HGGG6, LGGG10, HG6, and HGGG10) is investigated in nude mice bearing human LS174T colon carcinoma tumors. These conjugates differ in polymer molecular mass [97 kDa (H) or 35 kDa (L)], CDP-CPT linker structure [glycine (G) or triglycine (GGG)], and CPT loading [ca. 6 wt % (6) or 10 wt % (10)]. Maximum tolerable doses (MTDs) of the three conjugates, LGGG10, HG6, and HGGG10, are determined to be 36, 9, and 9 mg of CPT/kg, respectively, while the MTD of the CDP alone exceeds 240 mg/kg (highest value investigated). The three CDP-CPT conjugates with high polymer molecular masses (HGGG6, HG6, and HGGG10) demonstrate antitumor activity at their MTDs superior to that of CPT at the same amount and to that of irinotecan at its optimal dose. They also show tumor growth inhibition that is superior to that of the conjugate containing the low-molecular mass polymer (LGGG10) at the same dose of CPT. No significant effects of CPT weight loading or linker structure on tumor growth delay are observed. However, conjugates containing G appear to be less toxic than these with GGG. These antitumor studies demonstrate that the CDP-based conjugates of CPT exhibit tumor growth inhibition superior to that of CPT or irinotecan at the conditions employed in this study. The striking observation is that a short course of treatment with the polymer conjugates gives long-term control of tumor growth that does not occur with either CPT or irinotecan. Intracellular CDPs are demonstrated by analyzing cells that were cultured in the presence of rhodamine-labeled CDP (HRhod) containing medium using both confocal microscopy and flow cytometry. The long-term therapeutic efficacy of CDP-CPT conjugates observed in mice may in part be due to the sustained release of CPT from these conjugates in the acidic, intracellular compartments since these conjugates are shown to have significantly slower release rates at acidic pH than at physiological pH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15981921     DOI: 10.1021/mp049966y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  25 in total

1.  The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles.

Authors:  Kuan-Ju Chen; Li Tang; Mitch André Garcia; Hao Wang; Hua Lu; Wei-Yu Lin; Shuang Hou; Qian Yin; Clifton K-F Shen; Jianjun Cheng; Hsian-Rong Tseng
Journal:  Biomaterials       Date:  2011-11-08       Impact factor: 12.479

Review 2.  Nanotechnologies for biomedical science and translational medicine.

Authors:  James R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

3.  Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.

Authors:  Thomas Schluep; Jungyeon Hwang; Isabel J Hildebrandt; Johannes Czernin; Chung Hang J Choi; Christopher A Alabi; Brendan C Mack; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

4.  Anticancer Camptothecin-N-Poly(lactic acid) Nanoconjugates with Facile Hydrolysable Linker.

Authors:  Qian Yin; Rong Tong; Lichen Yin; Timothy M Fan; Jianjun Cheng
Journal:  Polym Chem       Date:  2014       Impact factor: 5.582

5.  Investigating the optimal size of anticancer nanomedicine.

Authors:  Li Tang; Xujuan Yang; Qian Yin; Kaimin Cai; Hua Wang; Isthier Chaudhury; Catherine Yao; Qin Zhou; Mincheol Kwon; James A Hartman; Iwona T Dobrucki; Lawrence W Dobrucki; Luke B Borst; Stéphane Lezmi; William G Helferich; Andrew L Ferguson; Timothy M Fan; Jianjun Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-14       Impact factor: 11.205

Review 6.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

7.  Tumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugates.

Authors:  Fengxi Liu; Min Li; Chunxi Liu; Yongjun Liu; Yanchao Liang; Fengshan Wang; Na Zhang
Journal:  Pharm Res       Date:  2013-09-17       Impact factor: 4.200

8.  Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates.

Authors:  Rong Tong; Jianjun Cheng
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

9.  Synthesis of water-soluble poly(α-hydroxy acids) from living ring-opening polymerization of O-benzyl-L-serine carboxyanhydrides.

Authors:  Yanbing Lu; Lichen Yin; Yanfeng Zhang; Zhang Zhonghai; Yunxiang Xu; Rong Tong; Jianjun Cheng
Journal:  ACS Macro Lett       Date:  2012-04-17       Impact factor: 6.903

10.  Drug-Initiated, Controlled Ring-Opening Polymerization for the Synthesis of Polymer-Drug Conjugates.

Authors:  Rong Tong; Jianjun Cheng
Journal:  Macromolecules       Date:  2012-02-27       Impact factor: 5.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.